Sinopep-Allsino Biopharmaceutical Co. Ltd. A Total Liabilities
Sinopep-Allsino Biopharmaceutical Co. Ltd. A total liabilities. Based on the latest financial reports, Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has total liabilities worth CN¥3.97 Billion CNY (≈ $580.42 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Sinopep-Allsino Biopharmaceutical Co. Lt to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2025)
Total liabilities of Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2025. This chart illustrates how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Sinopep-Allsino Biopharmaceutical Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
São Martinho S.A
SA:SMTO3
|
Brazil | R$16.54 Billion |
|
Wedge Industrial Co Ltd
SHE:000534
|
China | CN¥2.61 Billion |
|
Grand Plastic Technology
TWO:3131
|
Taiwan | NT$12.17 Billion |
|
GH Research PLC
NASDAQ:GHRS
|
USA | $12.86 Million |
|
Teva Pharmaceutical Industries Ltd
TA:TEVA
|
Israel | ILA32.10 Billion |
|
Turning Point Brands Inc
NYSE:TPB
|
USA | $386.61 Million |
|
Transwarp Technology (Shanghai) Co. Ltd. A
SHG:688031
|
China | CN¥288.00 Million |
|
Kontron AG
VI:KTN
|
Austria | €1.05 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Sinopep-Allsino Biopharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 688076 total assets.
Liquidity & Leverage Metrics
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Total Liabilities Ratios Explained
Sinopep-Allsino Biopharmaceutical Co. Ltd. A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2025)
The table below shows the annual total liabilities of Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥3.74 Billion ≈ $547.07 Million |
+56.05% |
| 2024-12-31 | CN¥2.40 Billion ≈ $350.57 Million |
+76.42% |
| 2023-12-31 | CN¥1.36 Billion ≈ $198.71 Million |
+127.30% |
| 2022-12-31 | CN¥597.41 Million ≈ $87.42 Million |
+87.78% |
| 2021-12-31 | CN¥318.14 Million ≈ $46.55 Million |
-25.94% |
| 2020-12-31 | CN¥429.55 Million ≈ $62.86 Million |
+5.92% |
| 2019-12-31 | CN¥405.54 Million ≈ $59.34 Million |
+52.76% |
| 2018-12-31 | CN¥265.47 Million ≈ $38.85 Million |
-8.55% |
| 2017-12-31 | CN¥290.27 Million ≈ $42.48 Million |
+131.92% |
| 2016-12-31 | CN¥125.16 Million ≈ $18.31 Million |
+1.46% |
| 2015-12-31 | CN¥123.35 Million ≈ $18.05 Million |
-28.72% |
| 2014-12-31 | CN¥173.05 Million ≈ $25.32 Million |
+6.09% |
| 2013-12-31 | CN¥163.12 Million ≈ $23.87 Million |
-- |
About Sinopep-Allsino Biopharmaceutical Co. Ltd. A
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was… Read more